September 11th 2024
EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.
September 10th 2024
Tom Martens, MD, Talks about the Vision for CGM as Part of Primary Care for Type 2 Diabetes
June 18th 2021MOBILE study lead author Tom Martens, MD, talks about the inherent benefits of CGM for T2D patients on basal insulin treated in primary care and also the challenges to this vision of patient care.